X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html
https://www.globenewswire.com//news-release/2023/10/21/2764294/0/en/Libtayo-cemiplimab-Neoadjuvant-Treatment-Demonstrates-Encouraging-Event-Free-Survival-in-Patients-with-Resectable-Cutaneous-Squamous-Cell-Carcinoma-CSCC.html
https://endpts.com/regeneron-reviews-plans-for-bispecific-antibody-after-two-patient-deaths/
https://www.prnewswire.com/news-releases/biolinerx-announces-initiation-of-randomized-phase-2-clinical-trial-in-first-line-metastatic-pancreatic-cancer-based-on-preliminary-data-from-single-arm-pilot-phase-combination-trial-includes-investigational-candidate-motixaforti-301878087.html
https://www.prnewswire.com/news-releases/the-combination-of-isa101b-and-libtayo-shows-promising-results-in-patients-whose-head-and-neck-cancer-progressed-on-anti-pd1-therapy-301841279.html
https://www.prnewswire.com/news-releases/isa-pharmaceuticals-to-present-first-clinical-trial-data-from-the-phase-ii-study-of-isa101b-and-libtayo-cemiplimab-combination-in-head-and-neck-cancer-at-the-asco-annual-meeting-2023-301833400.html
https://www.globenewswire.com/news-release/2023/05/25/2676764/0/en/Fianlimab-LAG-3-inhibitor-Combined-with-Libtayo-cemiplimab-Shows-Clinically-Meaningful-and-Durable-Tumor-Responses-Across-Key-Advanced-Melanoma-Patient-Populations.html
https://www.onclive.com/view/european-commission-approves-cemiplimab-plus-chemotherapy-for-first-line-pd-l1-nsclc
https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-combination-chemotherapy-receives-positive
https://www.globenewswire.com//news-release/2023/01/05/2583564/0/en/Sensei-Biotherapeutics-Announces-Clinical-Supply-Agreement-with-Regeneron-for-Phase-1-2-Clinical-Trial-Evaluating-SNS-101-a-Conditionally-Active-VISTA-blocking-Antibody-in-Combinat.html
https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-in-japan-for-advanced-or-recurrent-cervical-cancer-301709636.html
https://www.ema.europa.eu/en/documents/overview/libtayo-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/regenerons-libtayo-chalks-new-lung-cancer-win-alongside-bristols-yervoy-it-doesnt-matter
https://www.pharmaceutical-technology.com/news/ec-regeneron-immunotherapy-cervical-cancer/
https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-in-second-line-recurrent-or-metastatic-cervical-cancer-irrespective-of-pd-l1-expression-level-or-tumor-histology-301684532.html
https://www.biospace.com/article/regeneron-and-sanofi-carve-out-bigger-slice-of-nsclc-market-/
https://www.prnewswire.com/news-releases/libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-approved-by-the-fda-as-first-line-treatment-for-advanced-non-small-cell-lung-cancer-nsclc-301672231.html#:~:text=(NASDAQ%3A%20REGN)%20today%20announced,EGFR%2C%20ALK%20or%20ROS1%20aberrations
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097
https://www.prnewswire.com/news-releases/libtayo-cemiplimab-receives-positive-chmp-opinion-recommending-approval-to-treat-advanced-cervical-cancer-301649532.html
https://www.prnewswire.com/news-releases/positive-neoadjuvant-libtayo-cemiplimab-monotherapy-data-in-resectable-cutaneous-squamous-cell-carcinoma-presented-at-esmo-and-published-in-nejm-301621811.html
https://www.prnewswire.com/news-releases/roches-ventana-pd-l1-sp263-assay-receives-ce-ivd-approval-to-identify-patients-with-locally-advanced-and-metastatic-non-small-cell-lung-cancer-eligible-for-libtayo-301621285.html
https://www.fool.com/investing/2022/09/08/why-regeneron-pharmaceuticals-stock-is-crushing-it/
https://www.prnewswire.com/news-releases/oncoresponse-announces-clinical-supply-agreement-with-regeneron-to-evaluate-or2805-in-combination-with-libtayo-cemiplimab-in-patients-with-advanced-cancer-301617568.html
https://www.prnewswire.com/news-releases/esmo-presentations-of-libtayo-cemiplimab-fianlimab-and-novel-bispecific-antibodies-showcase-expanding-potential-of-regenerons-oncology-pipeline-in-multiple-cancers-301617433.html
https://www.fiercepharma.com/pharma/regenerons-libtayo-chemotherapy-combo-may-suffer-lung-cancer-delay-could-war-ukraine-be
https://www.prnewswire.com/news-releases/regeneron-completes-purchase-of-sanofis-stake-in-libtayo-cemiplimab-301579443.html
https://news.bloomberglaw.com/health-law-and-business/regeneron-buys-cancer-drug-from-sanofi-for-up-to-1-1-billion
https://www.fiercepharma.com/pharma/regeneron-and-sanofi-score-nice-approval-libtayo-cscc-giving-patients-fully-funded-access
https://www.prnewswire.com/news-releases/inovio-announces-survival-results-for-ino-5401--ino-9012-in-combination-with-libtayo-cemiplimab-in-patients-with-newly-diagnosed-gbm-at-asco-annual-meeting-2022-301556446.html
https://www.pharmatimes.com/news/nice_recommendation_for_sanofi_and_regenerons_cscc_treatment_1449291
https://www.fiercepharma.com/pharma/regeneron-sanofi-pull-application-for-libtayo-cervical-cancer-unable-to-align-fda
https://www.prnewswire.com/news-releases/fda-accepts-for-review-libtayo-cemiplimab-rwlc-in-combination-with-chemotherapy-for-first-line-treatment-of-advanced-nsclc-301463552.html
https://seekingalpha.com/article/4479133-sanofi-sny-ceo-paul-hudson-presents-jpmorgan-40th-annual-healthcare-conference-transcript
https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-approved-in-canada-for-the-first-line-treatment-of-adult-patients-with-non-small-cell-lung-cancer-expressing-pd-l1-in-50-of-tumour-cells-with-no-egfr-alk-or-ros1-aberrations-867251026.html
https://www.newswire.ca/news-releases/libtayo-r-cemiplimab-approved-in-canada-for-locally-advanced-basal-cell-carcinoma-bcc-patients-865659041.html
https://www.fiercepharma.com/pharma/regeneron-sanofi-take-another-stab-at-lung-cancer-libtayo-chemo-combo-win-should-merck-worry
https://www.prnewswire.com/news-releases/esmo-late-breaking-data-show-libtayo-cemiplimab-and-chemotherapy-first-line-treatment-combination-significantly-improved-overall-survival-in-patients-with-advanced-nsclc-301379960.html
https://www.prnewswire.com/news-releases/isa-pharmaceuticals-commences-patient-treatment-in-third-phase-2-clinical-trial-with-the-combination-of-isa101b-and-libtayo-cemiplimab-301370518.html
https://www.clinicaltrialsarena.com/analysis/cervical-cancer-treatment-libtayo-balstilimab/
https://www.fiercepharma.com/pharma/sanofi-regeneron-stop-libtayo-chemo-lung-cancer-trial-early-strong-survival-data
http://www.pharmatimes.com/news/sanofi,_regenerons_libtayo_cleared_for_basal_cell_carcinoma_1372217
https://www.prnewswire.com/news-releases/libtayo-cemiplimab-approved-by-the-european-commission-as-the-first-immunotherapy-indicated-for-patients-with-advanced-basal-cell-carcinoma-301319988.html
Market Place
Share 
